Brian A Jonas (Brian Jonas, B A Jonas)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 40

Top Topics

Acute Myeloid Leukemia

Newly Diagnosed

Top Venues

American journal of hematology

Leukemia & lymphoma

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Jorge E Cortes, Brian A Jonas, Gary Schiller, Alice Mims, Gail J Roboz, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Justin M Watts
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML). Leukemia & lymphoma 65 (8) (2024)
Hartmut Döhner, Keith W Pratz, Courtney D D DiNardo, Andrew H Wei, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Christian Recher, Andre C Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A Pollyea
Genetic Risk Stratification and Outcomes Among Treatment-Naive Patients With AML Treated With Venetoclax and Azacitidine. Blood (2024)
Keith W Pratz, Brian A Jonas, Vinod A Pullarkat, Michael J Thirman, Jacqueline S Garcia, Hartmut Döhner, Christian Recher, Walter Fiedler, Kazuhito Yamamoto, Jian-Xiang Wang, Sung-Soo Yoon, Ofir Wolach, Su-Peng Yeh, Brian Leber, Jordi Esteve, Jiri Mayer, Kimmo Porkka, Árpád Illés, Roberto M Lemoli, Mehmet Turgut, Grace Ku, Catherine Miller, Ying Zhou, Meng Zhang, Brenda J Chyla, Jalaja Potluri, Courtney D D DiNardo
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. American journal of hematology 99 (4) (2024)
Jorge E Cortes, Brian A Jonas, Gary Schiller, Alice Mims, Gail J Roboz, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Justin M Watts
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML). Leukemia & lymphoma (2024)
Jorge E Cortes, Brian A Jonas, Gary Schiller, Alice Mims, Gail J Roboz, Andrew H Wei, Pau Montesinos, P Brent Ferrell, Karen Wl Yee, Pierre Fenaux, Anthony Schwarer, Justin M Watts
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML). Leukemia & lymphoma 65 (8) (2024)
Keith W Pratz, Brian A Jonas, Vinod A Pullarkat, Michael J Thirman, Jacqueline S Garcia, Hartmut Döhner, Christian Recher, Walter Fiedler, Kazuhito Yamamoto, Jian-Xiang Wang, Sung-Soo Yoon, Ofir Wolach, Su-Peng Yeh, Brian Leber, Jordi Esteve, Jiri Mayer, Kimmo Porkka, Árpád Illés, Roberto M Lemoli, Mehmet Turgut, Grace Ku, Catherine Miller, Ying Zhou, Meng Zhang, Brenda J Chyla, Jalaja Potluri, Courtney D D DiNardo
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. American journal of hematology 99 (4) (2024)
Keith W Pratz, Brian A Jonas, Vinod A Pullarkat, Michael J Thirman, Jacqueline S Garcia, Hartmut Döhner, Christian Recher, Walter Fiedler, Kazuhito Yamamoto, Jian-Xiang Wang, Sung-Soo Yoon, Ofir Wolach, Su-Peng Yeh, Brian Leber, Jordi Esteve, Jiri Mayer, Kimmo Porkka, Árpád Illés, Roberto M Lemoli, Mehmet Turgut, Grace Ku, Catherine Miller, Ying Zhou, Meng Zhang, Brenda J Chyla, Jalaja Potluri, Courtney D D DiNardo
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. American journal of hematology (2024)
Keith W Pratz, Brian A Jonas, Vinod A Pullarkat, Michael J Thirman, Jacqueline S Garcia, Hartmut Döhner, Christian Recher, Walter Fiedler, Kazuhito Yamamoto, Jian-Xiang Wang, Sung-Soo Yoon, Ofir Wolach, Su-Peng Yeh, Brian Leber, Jordi Esteve, Jiri Mayer, Kimmo Porkka, Árpád Illés, Roberto M Lemoli, Mehmet Turgut, Grace Ku, Catherine Miller, Ying Zhou, Meng Zhang, Brenda J Chyla, Jalaja Potluri, Courtney D D DiNardo
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. American journal of hematology 99 (4) (2024)
Ryan J Beechinor, Brian A Jonas
This differentiation block will not stand, man: ivosidenib for MDS. Blood advances 8 (15) (2024)
Talha Badar, Ravi Narra, Alice S Mims, Michael G Heckman, Rory M Shallis, Sheikh Fahad, Cameron Hunter, Vamsi K Kota, Tamer Adel Othman, Brian A Jonas, Shreya Desai, Guilherme Sacchi de Camargo Correia, Anand Ashwin Patel, Adam S DuVall, Neil Palmisiano, Emily Curran, Zulfa Omer, Anjali S Advani, Ehab Atallah, Mark R Litzow
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. American journal of hematology (2024)
Stéphane de Botton, Pierre Fenaux, Karen W L Yee, Christian Recher, Andrew H Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn S Grove, Brian A Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K Hiwase, Joseph G Jurcic, Jürgen Krauter, Xavier G Thomas, Justin M Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge E Cortes
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood advances (2023)
Daria Gaut, Caspian Oliai, Jonathan Boiarsky, Shiliang Zhang, Amandeep Salhotra, Tali Azenkot, Vanessa E Kennedy, Vishesh Khanna, Karla Olmedo Gutierrez, Navika Shukla, Benjamin Moskoff, Gabriel Park, Michelle Afkhami, Anand Patel, Deepa Jeyakumar, Gabriel Mannis, Aaron C Logan, Brian A Jonas, Gary Schiller
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leukemia & lymphoma (2023)
Vera Pervitsky, Julie Guglielmo, Benjamin Moskoff, Roxie Kneen, Carol Leija, Deborah Sawicky, Margaret Li Krackeler, Brian A Jonas, Ryan J Beechinor
Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 31 (4) (2023)
Vera Pervitsky, Julie Guglielmo, Benjamin Moskoff, Roxie Kneen, Carol Leija, Deborah Sawicky, Margaret Li Krackeler, Brian A Jonas, Ryan J Beechinor
Characterization of a multidisciplinary team's role in hospital discharge for patients receiving hypomethylating agents with venetoclax as induction therapy for acute myeloid leukemia. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 31 (4) (2023)
Naval G Daver, Brian A Jonas, Bruno C Medeiros, Upen Patil, Mark Yan
Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti-PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia. Leukemia & lymphoma 63 (11) (2022)
Keith W Pratz, Courtney D D DiNardo, Dominik Selleslag, Junmin Li, Kazuhito Yamamoto, Marina Y Konopleva, Don Stevens, Hagop M Kantarjian, Fabiola Traina, Adriano Venditti, Jiri Mayer, Melissa Montez, Huan Jin, Yinghui Duan, Deanna Brackman, Jiuhong Zha, Jalaja Potluri, Michael Werner, Brian A Jonas
Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A. American journal of hematology 97 (11) (2022)
Keith W Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A Jonas, Pau Montesinos, Vladimir Ivanov, Andre C Schuh, Courtney D D DiNardo, Jan Novak, Vlatko Pejsa, Don Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H Wei, Cat N Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood cancer journal 12 (4) (2022)
Brian A Jonas, Andrew H Wei, Christian Recher, Courtney D D DiNardo, Jun-Ho Jang, Keith W Pratz, Panayiotis Panayiotidis, Pau Montesinos, Su-Peng Yeh, Vladimir Ivanov, Walter Fiedler, Takahiro Yamauchi, Yinghui Duan, Wellington Mendes, Jalaja Potluri, Björn Tews, Yishai Ofran
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. American journal of hematology 97 (8) (2022)
Tali Azenkot, Brian A Jonas
Clinical Impact of Measurable Residual Disease in Acute Myeloid Leukemia. Cancers 14 (15) (2022)
Jacqueline S Garcia, Yael Flamand, Livius Penter, Michael Keng, Benjamin Tomlinson, Lourdes M Mendez, Paul B Koller, Nicole Cullen, Yohei Arihara, Kathleen Lindahl Pfaff, Jacquelyn O Wolff, Andrew M Brunner, Ilene Galinsky, Asad Bashey, Joseph H Antin, Corey S Cutler, Vincent T Ho, Brian A Jonas, Marlise R Luskin, Martha Wadleigh, Eric S Winer, Alexandra Savell, Rebecca Leonard, Taylor Robertson, Matthew S Davids, Howard Streicher, Scott J Rodig, Jerome Ritz, Catherine J Wu, Daniel J DeAngelo, Donna Neuberg, Richard M Stone, Robert J Soiffer
Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood (2022)
Daniel A Pollyea, Keith W Pratz, Andrew H Wei, Vinod A Pullarkat, Brian A Jonas, Christian Recher, Sunil Babu, Andre C Schuh, Monique Dail, Yan Sun, Jalaja Potluri, Brenda J Chyla, Courtney D D DiNardo
Outcomes in Patients With Poor-risk Cytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Brian A Jonas, Courtney D D DiNardo, Nicola Stefano Fracchiolla, Alexander Pristupa, Kenichi Ishizawa, Jie Jin, Marina Y Konopleva, Yishai Ofran, Pau Montesinos, Tibor Kovacsovics, Jun-Ho Jang, Hagop M Kantarjian, Yinghui Duan, Jalaja Potluri, Michael Werner, Keith W Pratz
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study. American journal of hematology 97 (11) (2022)
Naval G Daver, Monique Dail, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A Pollyea, Agostino Tafuri, Joseph M Brandwein, Arnaud Pigneux, Bayard L Powell, Pierre Fenaux, Rebecca L Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G Ott, Wan-Jen Hong, Marina Y Konopleva, Michael Andreeff
Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood (2022)
Eric M Granowicz, Brian A Jonas
Targeting TP53 -Mutated Acute Myeloid Leukemia: Research and Clinical Developments. OncoTargets and therapy 15 (2022)
Vanessa E Kennedy, Gavin Hui, Tali Azenkot, Daria Gaut, Matthew J Wieduwilt, Caspian Oliai, Brian A Jonas, Varun Mittal, Aaron C Logan, Lori S Muffly, Gabriel N Mannis
Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia. American journal of hematology 97 (6) (2022)
Joseph M Tuscano, Christina Poh, Paul Kaesberg, Guilluame Luxardi, Alexander A Merleev, Alina Marusina, Ann Brunson, Aaron Rosenberg, Brian A Jonas, Emanual Maverakis
Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (17) (2021)
Aaron S Rosenberg, A Brunson, J Tuscano, Brian A Jonas, R Hoeg, Ted Wun, T H M Keegan
Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. Blood cancer journal 11 (1) (2021)
Tamer A Othman, Tali Azenkot, Benjamin N Moskoff, Matthew E Tenold, Brian A Jonas
Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia. Future oncology (London, England) 17 (23) (2021)
Brian A Jonas, Samantha C Fisch, Aaron S Rosenberg, Rasmus T Hoeg, Joseph M Tuscano, Mehrdad Abedi
Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia. American journal of hematology 96 (4) (2021)
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, Christian Recher, Andre C Schuh, Michael J Thirman, Jacqueline S Garcia, Courtney D D DiNardo, Vladimir Vorobyev, Nicola Stefano Fracchiolla, Su-Peng Yeh, Jun Ho Jang, Muhit Özcan, Kazuhito Yamamoto, Arpad Illes, Ying Zhou, Monique Dail, Brenda Chyla, Jalaja Potluri, Hartmut Döhner
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (8) (2021)
Tamer A Othman, Matthew E Tenold, Benjamin N Moskoff, Tali Azenkot, Brian A Jonas
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert review of hematology 14 (5) (2021)
Tamer Othman, Benjamin N Moskoff, Naseem Esteghamat, Rasmus T Hoeg, Aaron S Rosenberg, Brian A Jonas, Mehrdad Abedi, Carol Richman, Joseph M Tuscano
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas. Leukemia & lymphoma (2021)
Gautam Borthakur, Olatoyosi Odenike, Ibrahim Aldoss, David A Rizzieri, Thomas Prebet, Chris Chen, Relja Popovic, Dimple A Modi, Rujuta H Joshi, Johannes E Wolff, Brian A Jonas
A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer 127 (16) (2021)
Meilen Chang Muñoz, Jennifer A Murphy, Johannes E Wolff, Brian A Jonas
Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi). Case reports in hematology 2020 (2020)
Daniel A Pollyea, Keith Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Vinod A Pullarkat, Marina Y Konopleva, Michael J Thirman, Martha Arellano, Pamela S Becker, Brenda Chyla, Wan-Jen Hong, Qi Jiang, Jalaja Potluri, Courtney D D DiNardo
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study. American journal of hematology 96 (2) (2020)
Maria Galkin, Brian A Jonas
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. Core evidence 14 (2019)
Benjamin K Tomlinson, Joseph M Tuscano, Mehrdad Abedi, Jeanna Welborn, Mili Arora, Robert T O'Donnell, Ted Wun, Brian A Jonas
A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. American journal of hematology 94 (11) (2019)
Brian A Jonas, Daniel A Pollyea
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia. Leukemia 33 (12) (2019)
Jacob D Kjelland, Denis M Dwyre, Brian A Jonas
Acquired Elliptocytosis as a Manifestation of Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia. Case reports in hematology 2017 (2017)
Brian A Jonas, Carl Johnson, Dita Gratzinger, Ravindra Majeti
Alkylator-Induced and Patient-Derived Xenograft Mouse Models of Therapy-Related Myeloid Neoplasms Model Clinical Disease and Suggest the Presence of Multiple Cell Subpopulations with Leukemia Stem Cell Activity. PloS one 11 (7) (2016)